Sullivan K M, Appelbaum F R, Horning S J, Rosenberg S A, Thomas E D
Int J Cell Cloning. 1986;4 Suppl 1:94-106. doi: 10.1002/stem.5530040711.
Despite substantial progress in curative therapy of malignant lymphomas, some patients fail current treatment and die of refractory disease. Although Although high-dose chemotherapy and supralethal total body irradiation followed by bone marrow transplantation may salvage and cure a proportion of these refractory patients, treatment of such end-stage patients with marrow grafting often fails because of resistant disease or transplant-related complications. Using the analogy of transplantation in the early phases of acute and chronic leukemias, results of marrow transplant in Hodgkin's disease and non-Hodgkin's lymphoma might be improved if performed earlier in the course of the malignancy. The following collaborative report by the Seattle and Stanford groups examines current results of conventional lymphoma therapy to define subgroups of patients with "high-risk" lymphoma for whom early marrow transplant might be offered to control otherwise incurable disease.
尽管恶性淋巴瘤的治愈性治疗取得了重大进展，但仍有一些患者对当前治疗无效并死于难治性疾病。虽然大剂量化疗和超致死剂量全身照射后进行骨髓移植可能挽救并治愈一部分此类难治性患者，但对这些终末期患者进行骨髓移植治疗常常因疾病耐药或移植相关并发症而失败。借鉴急性和慢性白血病早期移植的经验，如果在恶性肿瘤病程早期进行骨髓移植，霍奇金病和非霍奇金淋巴瘤的移植结果可能会得到改善。西雅图和斯坦福研究小组的以下合作报告审视了传统淋巴瘤治疗的当前结果，以确定“高危”淋巴瘤患者亚组，对于这些患者可以提供早期骨髓移植以控制原本无法治愈的疾病。
